This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2005 May;6(5):257-8.

doi: 10.1016/S1470-2045(05)70142-X.

Who will benefit from treatment against EGFR?

Joaquín Arribas, José Baselga

PMID: 15863372
DOI: 10.1016/S1470-2045(05)70142-X

Comment

Who will benefit from treatment against EGFR?

Joaquín Arribas et al. Lancet Oncol. 2005 May.

. 2005 May;6(5):257-8.

doi: 10.1016/S1470-2045(05)70142-X.

Authors

Joaquín Arribas, José Baselga

PMID: 15863372
DOI: 10.1016/S1470-2045(05)70142-X

No abstract available

PubMed Disclaimer

Comment on

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.
Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A. Moroni M, et al. Lancet Oncol. 2005 May;6(5):279-86. doi: 10.1016/S1470-2045(05)70102-9. Lancet Oncol. 2005. PMID: 15863375 Clinical Trial.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Research Materials
- NCI CPTC Antibody Characterization Program
Miscellaneous
- NCI CPTAC Assay Portal